Healthcare Industry News: BioMarin Pharmaceutical
News Release - October 3, 2017
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of DirectorsSAN RAFAEL, Calif., Oct. 3, 2017 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Baxalta Chief Financial Officer and Chief Operations Officer, Robert J. Hombach, to its Board of Directors.
"I am honored to serve on the board of a company with a 20-year history of developing therapies that make a big difference for small patient populations," said Robert J. Hombach. "I am looking forward to working with BioMarin as it continues to build its current business, while advancing a robust pipeline during a time of exceptional growth."
About Mr. Hombach
Robert J. Hombach served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta, a biopharmaceutical company spun out from Baxter International in June 2015, until it was acquired by Shire PLC in June 2016. He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spin-off. From 2007 to 2011, Mr. Hombach also served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa. Prior to that, Mr. Hombach served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter.
Mr. Hombach currently serves on the Board of BCU, a national not-for-profit credit union, as chair of the Supervisory Committee. Previously, he served on the Board of Naurex, Inc., a private pharmaceuticals company acquired by Allergan in 2015, and was a member of the Audit, Compensation, and Transaction Committees. Mr.Hombach earned an MBA from Northwestern University's JL Kellogg Graduate School of Management, and a BS in Finance cum Laude from the University of Colorado.
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
BioMarin® is a registered trademarks of BioMarin Pharmaceutical Inc.
Source: BioMarin Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.